A Utah-based nonprofit pharmaceutical manufacturer, Civica Rx, is on the verge of commencing production at its newly constructed Petersburg plant, following two years of construction and a $140 million investment. With production set to begin this year, the insulin from the 140,000-square-foot facility will become available in the market by 2024 after undergoing FDA approval and validation processes.
Petersburg, VA